Oncostatin M
Latest Information Update: 18 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Cytokines
- Mechanism of Action Immunostimulants
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
Highest Development Phases
- Discontinued Cancer; Immunodeficiency disorders
